Home›Trial›NCT07372625
NCT07372625Phase 1RECRUITING

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

Study Summary

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Conditions
TP53 Y220C MutationAdvanced Solid Tumors
Interventions / Drugs
metformin hydrochloride 500 mg tabletrosuvastatin 10 mg tabletrepaglinide 0.5 mg tabletmidazolam hydrochloride syruprezatapopt
View on ClinicalTrials.gov ↗
Sponsor
PMVP
PMV Pharmaceuticals
p53 Reactivation
D39/100
Study Details
Enrollment14 participants
Primary Completion—
Lead SponsorPMV Pharmaceuticals, Inc
Data Retrieved2026-04-11 04:24:42.345876+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 14 participants
Sponsor Catalyst Profile

PMV Pharmaceuticals (PMVP) is the sponsoring company for this trial. BiotechSign currently grades this company D (39/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

PMVP Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.